VOGX
Vogenx, Inc. (VOGX)
Healthcare • NASDAQ • $16.15+11.15%
- Symbol
- VOGX
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $16.15
- Daily Change
- +11.15%
- Market Cap
- $215.84M
- Trailing P/E
- N/A
- Forward P/E
- N/A
- 52W High
- $38.41
- 52W Low
- $12.95
- Analyst Target
- $55.00
- Dividend Yield
- 0.00%
- Beta
- N/A
Vogenx, Inc. operates as a clinical-stage drug development company that develops therapeutics for metabolic including post-bariatric hypoglycemia, or PBH, and gastroparesis. Its products include drugs, such as Mizagliflozin and VGX-2857. It also offers VGX-001, a human monoclonal antibody for the treatment of type 1 diabetes (T1D). It caters to healthcare providers, physicians and third-party payors in the United States. The company was incorporated in 2021 and is based in Raleigh, North Carolina.
Company websiteResearch VOGX on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.